Conformational Aspects of Differences in Requirements for Oxytocin and Vasopressin Receptors

References

• Kinter L. B. Antidiuretic hormone antagonism in humans: are there predictors?. Vasopressin, S. Jard, R. Jamison. John Libey Eurotext, Paris 1991; 321–329
   Google Scholar
• Yamamura Y., Ogawa H., Chihara T., Kondo K., Onogawa T., Nakamura S., Mori T., Tominaga M., Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991; 252: 572–574
   PubMed Web of Science ®Google Scholar
• Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto S., Nakamura S., Onogawa T., Yamashita T., Hosokawa T., Mori T., Tominaga M., Yabuuchi Y. Characterisation of novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 1992; 105: 787–791
   PubMed Web of Science ®Google Scholar
• Serradeil-Le Gal C., Wagnon J., Lacour C., Christophe B., Barthélémy G., Guiraudou P., Nisato D., Le Fur G., Maffrand J-P., Cantau B., Barberis C., Guillon G., Jard S. Pharmacological profile of SR 49059, a potent non-peptide antagonist of V1 vasopressin receptors. Vasopressin, P. Gross, D. Richter, G. L. Robertson. John Libbey Eurotext, Paris 1993; 529–537
   Google Scholar
• Salituro G. M., Pettibone Dun.J., Clineschmidt B. V., Williamson J. M., Zink D. L. Potent. non-peptidic oxytocin receptor antagonists from a natural source. Bioorg. Med. Chem. Lett. 1993; 3: 337–340
   Web of Science ®Google Scholar
• Williams P. D., Bock M. G., Tung R. D., Garsky V. M., Perlow D. S., Erb J. M., Lundell G. F., Gould N. P., Whitter W. L., Hoffman J. B., Kaufman M. J., Clineschmidt B. V., Pettibone D. J., Freidinger R. M., Veber D. F. Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product. J. Med. Chem. 1992; 35: 3905–3918
   Google Scholar
• Evans B. E., Leighton J. L., Rittle K. E., Gilbert K. F., Lundell G. F., Gould N. P., Hobbs D. W., DiPardo R. M., Veber D. F., Pettibone D. J., Clineschmidt B. V., Anderson P. S., Freidinger R. M. Orally active. nonpeptide oxytocin antagonists. J. Med. Chem. 1992; 35: 3919–3927
   PubMed Web of Science ®Google Scholar
• Tarnowska M., Liwo A., Shenderovich M. D., Liepina I, Golbraikh A. A., Grzonka Z, Tempczyk A. A molecular mechanics study of the effect of substitution in position 1 on the conformational space of the oxytocin/vasopressin ring. J. Comput.-Aided Mol. Design. 1993; 7: 699–720
   Web of Science ®Google Scholar
• Liwo A., Tempczyk A., Oldziej S., Shenderovich M. D., Hruby V. J., Talluri S., Ciarkowski J., Kasprzykowski F., Lankiewicz L., Grzonka Z. Exploration of the conformational space of oxytocin and arginine-vasopressin in non-aqueous and aqueous solution using the Electrostatically-Driven Monte Carlo and molecular dynamics methods. J. Mol. Biol. 1994, submitted for publication
   Google Scholar
• Tarnowska M., Liwo A, Grzonka Z., Tempczyk A. Modified Free-Wilson analysis of the neurohypophyseal hormone analogs. I: Analogs of vasopressin-like activity. QSAR in Design of Bioactive Compounds, Vol. 2, M. Kuchař, J. R. Prous. Science Publishers, Barcelona 1991; 361–397
   Google Scholar
• Tarnowska M., Liwo A., Grzonka Z., Tempczyk A. Modified Free-Wilson analysis of the neurohypophyseal hormone analogs II: Analogs of oxytocin-like activity. QSAR in Design of Bioactive Compounds, Vol. 2, M. Kuchař, J. R. Prous. Science Publishers, Barcelona 1991; 399–436
   Google Scholar
• Barberis C., Balestre M. N., Mouillac B., Morel A., Elands J., Hoflack J., Trumpp-Kallmeyer S., Hibert M. F., Jard S. Site-directed mutagenesis of V1a vasopressin receptor: identification of amino-acids involved in ligand binding. Vasopressin, P. Gross, D. Richter, G. L. Robertson. John Libbey Eurotext, Paris 1993; 69–78
   Google Scholar
• Gajewski J. J., Gilbert K. E. PCMODEL ver. 4.0. Serena Software, Bloomington 1991, Indiana, USA, Box 3076
   Google Scholar
• Gajewski J. J., Gilbert K. E., McKevey J. Advances in Molecular Modelling. A Research Annual, Vol. 2, D. Liotta. Jai Press Inc., London 1990; 65
   Google Scholar
• Shenderovich M. D., Wilke S., Kövér K., Hruby V., Liwo A., Ciarkowski J. Solution conformation of a potent antagonist of oxytocin. Pol. J. Chem. 1994; 68, in press
   Google Scholar
• Urry D. W., Ohnishi, Walter R. Secondary structure of the cyclic moiety of the peptide hormone oxytocin and its deamino analog. Proc. Natl. Acad. Sci. USA 1970; 66: 111–116
   PubMed Web of Science ®Google Scholar
• Hill P. S., Chan W. Y., Hruby V. J. Oxytocin antagonists with changes in the Asn5 position shed light on hormone-oxytocin receptor interactions. Int. J. Peptide Protein Res. 1991; 38: 32–37
   Google Scholar
• Bock M. G., Carroll L. A., Di Pardo R. M., Evans B. E., Leighton J. L., Rittle K. E., Gilbert K. F., Lundell G. F., Gould N. P, Whitter W. L., Williams P. D., Perlow D. S., Pettibone D. J., Clineschmidt B. V., Veber D. F., Freidinger R. M. Development and biological activity of novel non-peptide oxytocin antagonists. Vasopressin, P. Gross, D. Richter, G. L. Robertson. John Libbey Eurotext, Paris 1993; 539–547
   Google Scholar
• Shenderovich M. D., Liwo A., Oldziej S., Ciarkowski J. Oxytocin antagonists' pharmacophore. Pol. J. Chem. 1994; 68: 929–938
   Google Scholar
• Langs D. A., Smith G. D., Stezowski J. Structure of pressinoic acid: the cyclic moiety of vasopressin. Science 1986; 232: 1240–1242
   PubMed Web of Science ®Google Scholar